A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability and Immunogenicity of 2 and 3 Doses of 13vPnC in HIV-Infected Subjects 6 Years of Age and Older Who Have Not Been Previously Immunized With Pneumococcal Vaccine
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Pfizer
- Enrollment
- 303
- Locations
- 11
- Primary Endpoint
- Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in All Participants
Study Overview
Brief Summary
The study will evaluate the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 6 years of age or older who have not been previously immunized with a pneumococcal vaccine. All subjects will receive 3 doses of 13vPnC and 1 dose of 23-valent pneumococcal polysaccharide vaccine (23vPS), with each dose given approximately 1 month apart.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 6 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Human immunodeficiency virus (HIV)-infected subjects aged 6 years or older
- •Viral load < 50,000 copies/mL and CD4+ T cell count >= 200/uL within 6 months before study vaccination
- •Receiving stable highly active antiretroviral therapy (HAART) or not currently receiving any antiretroviral therapy
- •No previous vaccination with a pneumococcal vaccine
- •Subject or parent/legal guardian able to complete an electronic diary
Exclusion Criteria
- •Acquired immune deficiency syndrome (AIDS) at time of enrollment
- •Current illicit substance and/or alcohol abuse
- •History of active chronic viral hepatitis
- •Previous anaphylactic reaction to a vaccine or vaccine-related component
- •Serious chronic disorders including metastatic malignancy and end-stage renal disease
Arms & Interventions
1
3 doses of 13vPnC and 1 dose of 23vPS, each dose given approximately 1 month apart
Intervention: 13-valent Pneumococcal Conjugate Vaccine (13vPnC) (Biological)
1
3 doses of 13vPnC and 1 dose of 23vPS, each dose given approximately 1 month apart
Intervention: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) (Biological)
1
3 doses of 13vPnC and 1 dose of 23vPS, each dose given approximately 1 month apart
Intervention: Blood draw (Procedure)
Outcomes
Primary Outcomes
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in All Participants
Time Frame: 1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.
Secondary Outcomes
- Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants(1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3)
- Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric and Adult Participants(1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3)
- Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants(1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3)
- Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric, Adult and All Participants(1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3)